Linezolid-resistance Staphylococcus aureus – Prevalence, Emerging Resistance Mechanisms, Challenges and Perspectives

Staphylococcus aureus, an opportunistic pathogen, can root several infections viz skin and tissue infections, bacteraemia, food poisoning, pneumonia, many other clinical conditions with some variations of virulence factors. In treatment caused by this Gram-positive antibiotics are being used importantly Methicillin Vancomycin. This pathogen has high capability antibiotic resistance development had evolved new strains such as Methicillin-resistant aureus (MRSA), Vancomycin-resistant (VRSA). Meta-analysis in Ethiopia showed that pooled prevalence MRSA environment, food, animal, human was 54%, 77%, 15%, 38% respectively (2022). Risk isolates from burn ICU 55 % higher (2018). Bangladesh, 37.1% frozen meat chicken (2021) were identified MRSA. problem is dealt a novel drug called Linezolid which been proved effective against both VRSA. Exacerbating the situation, shown unprecedented means number mechanisms. Its reporting since adoption drug, but minute ratio at one time/place to very percentage another time/place. inconsistent must not be ignored, its surveillance should augmented critical for fighting microbial infections. review highlights worldwide reports either wildtype or Vancomycin have past 2 decades. At same time where incidences Resistant (LRSA) indications reporting, there call comprehensive strategies overcome challenge resistance.